1 |
Brody H. Lung cancer[J]. Nature, 2020, 587(7834): S7. DOI: 10.1038/d41586-020-03152-0
|
2 |
Cheung CHY, Juan HF. Quantitative proteomics in lung cancer[J]. J Biomed Sci, 2017, 24(1): 37. DOI: 10.1186/s12929-017-0343-y
|
3 |
Li FB, Gu FM, Li Q, et al. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway[J]. J Biochem Mol Toxicol, 2021, 35(5): e22726. DOI: 10.1002/jbt.22726
|
4 |
Fang YW, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer[J]. Genomics Proteomics Bioinformatics, 2016, 14(1): 42-54. DOI: 10.1016/j.gpb.2015.09.006
|
5 |
Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: archive for functional genomics data sets: 10 years on[J]. Nucleic Acids Res, 2011, 39(Database issue): D1005-10. DOI: 10.1093/nar/gkq1184
|
6 |
Temraz S, Mukherji D, Alameddine R, et al. Methods of overcoming treatment resistance in colorectal cancer[J]. Crit Rev Oncol Hematol, 2014, 89(2): 217-30. DOI: 10.1016/j.critrevonc.2013.08.015
|
7 |
Zhang MH, Yang Y, Zhao Y, et al. LncRNA DQ786243 expression as a biomarker for assessing prognosis in patients with gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(8): 2304-9.
|
8 |
Zhang Q, Chen BY, Liu P, et al. XIST promotes gastric cancer (GC) progression through TGF‑β1 via targeting miR-185[J]. J Cell Biochem, 2018, 119(3): 2787-96. DOI: 10.1002/jcb.26447
|
9 |
Yu WJ, Sun ZN, Yang L, et al. lncRNA PTAR promotes NSCLC cell proliferation, migration and invasion by sponging microRNA-101[J]. Mol Med Rep, 2019, 20(5): 4168-74.
|
10 |
Chen S, Zhou L, Ran RZ, et al. Circ_0016760 accelerates non-small-cell lung cancer progression through miR-646/AKT3 signaling in vivo and in vitro [J]. Thorac Cancer, 2021, 12(23): 3223-35. DOI: 10.1111/1759-7714.14191
|
11 |
Bian ZH, Zhang JW, Li M, et al. LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling[J]. Clin Cancer Res, 2018, 24(19): 4808-19. DOI: 10.1158/1078-0432.ccr-17-2967
|
12 |
Liang M, Li YK, Dai TT, et al. lncRNA FEZF1-AS1 regulates biological behaviors of cervical cancer by targeting miRNA-1254[J]. Food Sci Nutr, 2021, 9(9): 4722-37. DOI: 10.1002/fsn3.2315
|
13 |
周丽亚. FEZF1-AS1和AKT3在中晚期肺腺癌中的表达及与EGFR-TKIs疗效关系的研究[D]. 蚌埠: 蚌埠医学院, 2022: 1-2.
|
14 |
Shi CL, Sun L, Song YS. FEZF1-AS1: a novel vital oncogenic lncRNA in multiple human malignancies[J]. Biosci Rep, 2019, 39(6): BSR20191202. DOI: 10.1042/bsr20191202
|
15 |
Li M, Wei L, Liu PY, et al. Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5[J]. Exp Biol Med, 2021, 246(2): 177-86. DOI: 10.1177/1535370220963197
|
16 |
Luo HL, Luo T, Liu JJ, et al. Macrophage polarization-associated lnc-Ma301 interacts with caprin-1 to inhibit hepatocellular carcinoma metastasis through the Akt/Erk1 pathway[J]. Cancer Cell Int, 2021, 21(1): 422. DOI: 10.1186/s12935-021-02133-1
|
17 |
Wang J, Tan LR, Yu XT, et al. lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942/TNS1 axis and is positively regulated by the m6A reader YTHDC2[J]. Mol Cancer, 2022, 21(1): 229. DOI: 10.1186/s12943-022-01705-7
|
18 |
Liu WW, Li Y, Zhang Y, et al. Circulatinglong non-coding RNA FEZF1-AS1 and AFAP1-AS1 serve as potential diagnostic biomarkers for gastric cancer[J]. Pathol Res Pract, 2020, 216(1): 152757. DOI: 10.1016/j.prp.2019.152757
|
19 |
Hui YJ, Yang Y, Li DP, et al. LncRNA FEZF1-AS1 modulates cancer stem cell properties of human gastric cancer through miR-363-3p/HMGA2[J]. Cell Transplant, 2020, 29: 963689720925059. DOI: 10.1177/0963689720925059
|
20 |
Zhu DW, Huang J, Liu N, et al. PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration[J]. Cell Death Dis, 2021, 12(8): 730. DOI: 10.1038/s41419-021-03981-5
|
21 |
Wei YJ, Chen W, Li ZH, et al. EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling[J]. FASEB J, 2022, 36(12): e22647. DOI: 10.1096/fj.202200913r
|
22 |
Sun T, Xu YJ, Jiang SY, et al. Suppression of the USP10/CCND1 axis induces glioblastoma cell apoptosis[J]. Acta Pharmacol Sin, 2021, 42(8): 1338-46. DOI: 10.1038/s41401-020-00551-x
|
23 |
Chen G, Hu M, Qu XS, et al. MicroRNA-584 directly targets CCND1 and inhibits cell proliferation and invasion in pancreatic cancer[J]. Mol Med Rep, 2019, 19(1): 719-26.
|
24 |
Hao XY, Jia QQ, Yuan JL, et al. MicroRNA-195 suppresses cell proliferation, migration and invasion in epithelial ovarian carcinoma via inhibition of the CDC42/CCND1 pathway[J]. Int J Mol Med, 2020, 46(5): 1862-72.
|
25 |
Liu DC, Liu HG, Gan JD, et al. LY2874455 and abemaciclib reverse FGF3/4/19/CCND1 amplification mediated gefitinib resistance in NSCLC[J]. Front Pharmacol, 2022, 13: 918317. DOI: 10.3389/fphar.2022.918317
|
26 |
Chen XD, Cheng P, Hu CH. LncRNA FEZF1-AS1 accelerates the migration and invasion of laryngeal squamous cell carcinoma cells through miR-4497 targeting GBX2[J]. Eur Arch Otorhinolaryngol, 2021, 278(5): 1523-35. DOI: 10.1007/s00405-021-06636-5
|
27 |
Xie RJ, Liu CB, Liu LF, et al. Long non-coding RNA FEZF1-AS1 promotes rectal cancer progression by competitively binding miR-632 with FAM83A[J]. Acta Biochim Biophys Sin, 2022, 54(4): 452-62. DOI: 10.3724/abbs.2022022
|